PDS Biotechnology (PDSB) Tops Q1 EPS by 2c May 13, 2026 07:03AM
PDS Biotech receives patent allowance for PDS0101 cancer therapy Jan 22, 2026 08:45AM
PDS Biotech gains FDA alignment on survival endpoint for cancer trial Jan 9, 2026 08:45AM
PDS Biotechnology receives patent for PDS0101 in Japan Dec 9, 2025 08:04AM
PDS Biotech schedules FDA meeting on accelerated approval pathway Dec 2, 2025 08:32AM


Nov 13, 2025 04:08PM PDS Biotechnology (PDSB) Tops Q3 EPS by 2c
Nov 10, 2025 08:30AM PDS Biotechnology presents immunotherapy data at cancer conference
Oct 29, 2025 08:37AM PDS Biotech seeks expedited approval pathway for head and neck cancer drug
Sep 18, 2025 08:45AM PDS Biotech reports extended survival in head and neck cancer trial
Aug 29, 2025 04:16PM PDS Biotechnology (PDSB) Files $200M Mixed Shelf
Aug 13, 2025 07:25AM PDS Biotechnology (PDSB) Tops Q2 EPS by 1c
Jul 11, 2025 06:38AM H.C. Wainwright Reiterates Buy Rating on PDS Biotechnology Corp (PDSB)
Jul 10, 2025 08:03AM PDS Biotech colorectal cancer trial advances to stage 2 expansion
Jun 11, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on PDS Biotechnology Corp (PDSB)
Jun 2, 2025 08:03AM PDS Biotechnology (PDSB) Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune HPV to Treat Head and Neck Cancers
May 22, 2025 05:32PM PDS Biotechnology (PDSB) announces abstracts on Versamune HPV studies
May 14, 2025 04:23PM PDS Biotechnology (PDSB) Tops Q1 EPS by 11c
Mar 28, 2025 06:40AM PDS Biotechnology Corp (PDSB) PT Lowered to $13 at H.C. Wainwright
Mar 10, 2025 06:51AM H.C. Wainwright Reiterates Buy Rating on PDS Biotechnology Corp (PDSB)
Mar 7, 2025 08:45AM PDS Biotechnology (PDSB) Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
Feb 27, 2025 08:00AM PDS Biotechnology (PDSB) Announces $22M Offering at $1.50/sh
Feb 24, 2025 08:00AM PDS Biotechnology (PDSB) Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research
Feb 5, 2025 08:02AM PDS Biotechnology (PDSB) Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Nov 14, 2024 08:00AM PDS Biotechnology (PDSB) Tops Q3 EPS by 1c
Oct 3, 2024 06:59AM H.C. Wainwright Reiterates Buy Rating on PDS Biotechnology Corp (PDSB)
Oct 2, 2024 08:02AM PDS Biotechnology (PDSB) Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
Sep 16, 2024 07:01AM PDS Biotechnology (PDSB) Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024
Aug 13, 2024 08:10AM PDS Biotechnology (PDSB) Tops Q2 EPS by 10c
Aug 1, 2024 07:45AM PDS Biotechnology (PDSB) Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer
Jun 12, 2024 08:01AM PDS Biotechnology (PDSB) Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer
Jun 12, 2024 07:37AM PDS Biotechnology Corp (PDSB) PT Lowered to $9 at B.Riley